Get started

Modernainc

Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine. Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot. From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products. The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet. Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
NASDAQ:MRNALong
by DEXWireNews
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects. One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology. In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market. Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years. Technical Analysis Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum. Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs. In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NASDAQ:MRNALong
by DEXWireNews
Moderna's Road to Recovery Moderna has recently garnered attention for its significant rebound after a challenging 2023. The biotech company, primarily known for its groundbreaking COVID-19 vaccine, is poised for a transformative journey ahead, with a strategic pipeline that extends far beyond pandemic management. This Idea delves into the recent surge in Moderna's stock, the pivotal role of Oppenheimer's upgrade, and the promising prospects that lie ahead. The Resilience of Moderna Stock: Following a tumultuous year in 2023, marked by a 45% dip in stock value, Moderna is experiencing a remarkable resurgence. A recent 15% surge was triggered by Oppenheimer's optimistic upgrade to "outperform." The upgrade reflects the financial firm's confidence in Moderna's ability to diversify its product portfolio, projecting the introduction of five new products by 2026. This shift in sentiment underscores the market's recognition of Moderna's potential to pivot beyond its flagship COVID-19 vaccine. Diversification Beyond COVID-19: Moderna's dependency on COVID-19 vaccine sales took a toll in 2023, prompting the need for diversification. Oppenheimer analyst Hartaj Singh highlights Moderna's promising pipeline, suggesting the potential launch of several products over the next 12 to 18 months. Among these, an experimental vaccine targeting respiratory syncytial virus (RSV) for older adults stands out, with a potential FDA decision in April 2024. The company's experimental flu vaccine, displaying superior immune response in trials, could also secure approval in 2024 or 2025. Additionally, the prospect of an FDA approval for an experimental personalized cancer vaccine further enhances Moderna's growth potential. Financial Outlook and Market Response: Despite a projected dip in COVID-19 vaccine sales in 2024 due to factors like vaccine fatigue, Moderna's overall sales are expected to surge in 2025 and beyond. The company's third-quarter earnings report anticipates revenue to rebound to $4 billion in 2025 after a temporary decline to $4 billion in 2024. Moderna's commitment to launching up to 15 products in the next five years aligns with its goal to diversify revenue streams and minimize reliance on pandemic-related products. Technical Analysis and Investor Sentiment: A crucial aspect of Moderna's recent success lies in its positive technical analysis. Breaking the ceiling of the falling trend in the medium-long term signifies a slower rate of decline. While the stock has met the short-term objective at $86.84, the technical indicators suggest cautious optimism. With support at $70.00 and resistance at $118, the stock appears well-positioned for potential growth. Conclusion Moderna's stock journey reflects a company resilient in the face of challenges, capitalizing on opportunities beyond the pandemic. Oppenheimer's upgrade and the positive technical analysis signal a turning point for Moderna, with a diversified product portfolio offering a hedge against future uncertainties. As the pharmaceutical giant marches towards its goal of launching innovative products, investors are increasingly viewing Moderna as more than just a COVID-19 play, but a promising player in the broader healthcare landscape.
NASDAQ:MRNALong
by DEXWireNews
Moderna, Inc. Flashes Bearish SignalsWe have a lower high, compare this past 16-November to 4-August. We also have a clear bearish pattern in the form of a rising wedge. Going by the candlesticks, we can spot some bearish signals there as well. 16-Nov. Doji is a bearish candle. 18-Nov. another bearish candle, confirmation of the previous one. Today we gapped lower which gives strength to the bears. A correction can easily form here. CHANGE MRNA needs to break and close above 188.65 for the bullish momentum to resume. Trading below 185 spells doom. Support levels/targets are marked in light blue. Namaste.
NASDAQ:MRNAShort
by AlanSantana
1
Moderna at key resistance? Moderna Short Term We look to Sell at 183.71 (stop at 203.39) Preferred trade is to sell into rallies. Previous resistance located at 190.00. Trading within a Bearish Channel formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 121.74 and 94.19 Resistance: 190.00 / 220.00 / 495.00 Support: 156.00 / 120.00 / 100.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Shooting Star on Moderna? Moderna Short Term We look to Sell at 146.42 (stop at 154.23) Preferred trade is to sell into rallies. Price action has posted a bearish Shooting Star and is negative for short-term sentiment. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 122.21 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 120.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Feeling sick? (Moderna)Moderna Short Term We look to Sell at 133.52 (stop at 141.88) Preferred trade is to sell into rallies. Prices expected to stall near trend line resistance. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 105.41 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 116.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Moderna Analysis 11.12.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
Editors' picks
NASDAQ:MRNA
by basictradingtv
100
MRNA Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NASDAQ:MRNAShort
by hadimozayan
MODERNA Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NASDAQ:MRNAShort
by hadimozayan
4
MRNA Moderna vs PFE Pfizer | Head and Shoulders patternIf you haven`t longed Moderna with me from here: Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share. On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the portfolio, a market cap almost 4 times higher, 198.973B and positive earnings of 9.62Bil. The pay also great dividends, btw, 4.38% DIV YIELD on a decent 20.82 P/E ratio . If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNAShort
by TopgOptions
8
Moderna (MRNA) Bounce ComingApproaching 200 MA Gap filled Oversold Revenue will sky rocket with all of the vaccine orders MACD is improving Yes its pharma, yes it looks like a dumpster fire and we cant trust them BUT I can't help it. I see a bounce form $95-105 range to $135-155 range if not back to ATH after all the vaccine orders materialize in actual revenues. We might still dip more but keep a close eye on it. We dont even have to worry about technicals, Fauci and the boys will pump this up.
NASDAQ:MRNALong
by bossmodetrader
4
MODERNA MRNA Trend Analysis Shows Time To InvestRight now, stocks in companies developing a vaccine against the virus look very attractive to investors. Knowing how to correctly determine the trend and price movement, you can make a profitable investment and get a lot of profit. We have developed a script that analyzes price movements in real time, taking into account current and past trends, and offers signals to buy company shares MODERNA NASDAQ:MRNA . The script is developed on the basis of the following indicators: Bollinger Bands and Moving Average, Supertrend indicator. Signals are trending and will help complement your trading strategy and more accurately determine entry points. This idea is useful for intraday traders timeframes 1H, 2H, 4H.
NASDAQ:MRNA
by atmospherestockstrade
MRNA Moderna vaccine 94.5% effective in Phase 3 trial!This was my previews post about Moderna: The indicators are still bullish. The price of the stock grew 5X since the beginning of the year. 11/16/2020 Oppenheimer Boost Price Target ➝ $157.00 11/16/2020 Piper Sandler Boost Price Target ➝ $166.00 The traditional method of creating vaccines – introducing a weakened or dead virus, or a piece of one, to stimulate the body's immune system – takes over a decade on average, according to a 2013 study. One pandemic flu vaccine took over eight years while a hepatitis B vaccine was nearly 18 years in the making. Moderna's vaccine went from gene sequencing to the first human injection in 63 days. Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines. BioNTech's vaccine, for example, must be transported at minus 70 degrees Celsius, though Moderna said on Monday it can ship its candidate in normal refrigerators. (Reuters) If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNALong
by TopgOptions